RT Journal Article
SR Electronic
T1 Roflumilast significantly decreased inflammatory biomarkers in induced sputum in current smokers patients with severe chronic obstructive pulmonary disease
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P3460
VO 40
IS Suppl 56
A1 Alizamin Sadigov
A1 Gabrail Mammadov
A1 Adalyat Abdullayev
YR 2012
UL http://erj.ersjournals.com/content/40/Suppl_56/P3460.abstract
AB The aim our study was identify the impact of ROFLUMILAST to inflammatory biomarkers in induced sputum in current smokers patients with severe COPD. All patients were divided in two groups:1)24 patients have received BUDESONIDE/FORMOTEROL 640/18 mcg/day and ROFLUMILAST 500 mcg/day;2)24 patients have received only BUD/FORM. 640/18 mcg/day.All patients were current smokers and observed during 6 months.In patients with severe COPD whom applied ROFLUMILAST together with BUD/FORM. the level of inflammatory biomarkers in induced sputum significantly decreased after 6 months therapy.In patients group with ROFLUMILAST therapy the number of neutrophils decreased importantly(39,1 +_9,8 vs 20,4+_6,7%,p<0,001).This decreasing at the same time was accompanied with reducing the level of pro-inflammatory cytokins in induced sputum(IL-8 was decreased up to 15,7+_4,2 pg/ml vs 29,6 +_6,9 pg/ml before treatment,p<0,001).The anti-inflammatory influence of ROFLUMILAST was accompanied with improving of lung function(FEV1 increased up to 48,7+_6,4% vs 40,4+_9,1% before treatment,p<0,05).Our study shown that, the added ROFLUMILAST to the therapy with BUD/FORM. significantly decreased the level of inflammatory biomarkers in current smokers with severe COPD.Summarized the follows we can conclude that,ROFLUMILAST as additional drug to the therapy with BUD/FORM. through reducing the severity of chronic inflammation may improve the lung function of the current smokers patients with severe COPD.